Koca, SinanBesiroglu, MehmetOzcelik, MelikeKaraca, MustafaBilici, MehmetHacioglu, BekirDogu, Gamze G.2024-06-122024-06-1220211078-15521477-092Xhttps://doi.org/10.1177/1078155220924075https://hdl.handle.net/20.500.14551/23056Purpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. Materials and methods We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. Results The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade >= 3 toxicities were fatigue, anorexia, weight loss, and liver disorder. Conclusion Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.en10.1177/1078155220924075info:eu-repo/semantics/closedAccessPazopanibSoft Tissue SarcomaTargeted TherapyRandomized Phase-IiSpanish GroupGemcitabineRiskArticle273541546Q4WOS:0005340519000012-s2.0-8508483081732419618Q3